Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hologic, Inc. (NASDAQ: HOLX) is set to release its financial results for Q2 2023 on May 1 after market close. A conference call will follow at 4:30 p.m. ET, where management will provide insights into the results. Interested participants can join the call by dialing the provided numbers or by click here to join. A replay will be available on Hologic's investor website.
Hologic, Inc. (NASDAQ: HOLX) will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. Eastern Time in Boston, MA. The conference runs from March 6-8 and includes various presentations and panel discussions on the health care industry. Hologic's presentation will be available via a live webcast on the company's investor website for 30 days post-event. Hologic is dedicated to enhancing women’s health through early detection and treatment innovations.
Summary not available.
Hologic, Inc. (NASDAQ: HOLX) announced that the U.S. Court of Appeals for the Federal Circuit upheld a 2021 ruling that invalidated a Minerva patent related to its NovaSure system. The court determined Minerva's patent was invalid due to a delay in filing after showcasing a prototype. This decision aligns with the previous district court judgment, which favored Hologic just before trial. In a related case, Minerva was ordered to pay Hologic over $7.4 million for infringing a Hologic patent. NovaSure, approved by the FDA in 2001, is a minimally invasive procedure for treating abnormal uterine bleeding, with a 77.7% efficacy rate and 92.8% patient satisfaction.
Hologic Inc. announced the approval of its NovaSure® V5 global endometrial ablation device in Canada and Europe. This advanced version features enhanced technology aimed at treating diverse cervical and uterine anatomies, enhancing patient outcomes. With over 3 million women treated globally, the NovaSure V5 offers a 97% patient satisfaction rate and an 87% hysterectomy avoidance rate at ten years post-procedure. Key improvements include an updated cervical seal and enhanced accuracy markings. The company emphasizes ongoing commitment to innovation in women's health.